Introduction
During past several years, the presence of carbapenemase-producing Enterobacteriaceae (CPE) has become a major health-care concern. The occurrence of CPE harbouring strains makes the situation worrisome, as treatment of such cases becomes challenging often leading to therapeutic failure. [1] If the mechanism of resistance is plasmid-mediated the spread of such resistance is rapid; requiring judicious and rapid screening of patients admitted to tertiary -care facilities. Screening of patients for CPE allows Health-care-workers to put into practice strict contact isolation protocols, thus preventing its further spread. Early screening by implementing an assay that is rapid, sensitive and non-laborious to identify CPE -harbouring strains is essential. The following study was performed: (a) To evaluate GeneXpert MDRO-assay (bla NDM , bla VIM , bla KPC ) directly on to the rectal swabs. (b) To compare GeneXpert MDRO-assay results with an in-house developed multiplex-polymerase chain reaction (MPCR).
in the MDRO cartridge, where as 12% (n = 3) had a different resistant mechanism (bla OXA ) (in house-multiplex PCR). [2] The concordance between the phenotypic and Xpert MDRO-assay was 100% for the target genes incorporated in the MDRO cartridge. The assay rapidly identified CPE-harbouring strains directly from rectal swabs. Furthermore, in case of 10 culture negative samples (culture negative [n = 7] + target gene not incorporated in the cartridge [n = 3]), 90% (n = 9) were Xpert negative and one sample was Xpert positive.
bla NDM is the most prevalent CPE in the subcontinent. [3] The presence of bla NDM alone confers resistance to most of the clinically treatable antibiotics. The present study highlights the fact that among the patients infected with CRE, 62.5% (20/32) cases carried bla NDM alone, 9.3% (3/32) had both bla NDM and bla VIM and 3.1% (1/32) had bla VIM as the mechanism of resistance whereas 25% (8/32) [ Table 1 ] had none of the targeted carbapenemases. Moreover, there are reports of co-existence of OXA-181 and NDM-1. [4] In addition, an in-house multiplex PCR was performed on the bacterial isolates showed 31.8% (7/22) harbored both bla OXA181/48 and bla In order to resolve the discrepancies (26% [6/23]) between GeneXpert MDRO-assay performed on rectal swab and in-house MPCR on isolates; GeneXpert MDRO-assay was performed on specific (discrepant) isolates no 1, 6, 7, 14, 19 and 27. The results of discrepant isolates are listed in Table 2 . The current need is early screening, active surveillance, good hand hygiene, cohorting infected patients from the uninfected ones and judicious use of antibiotics. [5] This necessitates implementation of assays that are rapid, 
Conclusion
The GeneXpert assay is a rapid screening test for identification of CPE. In addition to the above targets (NDM, VIM, KPC), the newer assays can detect OXA and IMP variants. 
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